Open-Label, Randomized, 3-Way Crossover Design to Assess the Relative Bioavailability of JNJ-42756493 Tablets
Phase of Trial: Phase I
Latest Information Update: 03 Nov 2015
At a glance
- Drugs Erdafitinib (Primary)
- Indications Cancer; Lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 29 Oct 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 07 Jul 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 15 Jun 2015 New trial record